Effects of Remimazolam on Intracellular Calcium Dynamics in Myotubes Derived from Patients with Malignant Hyperthermia and Functional Analysis of Type 1 Ryanodine Receptor Gene Variants

Overview

Journal Genes (Basel)

Publisher MDPI

Date 2023 Nov 25

PMID 38002952

Authors

Hirotsugu Miyoshi

Sachiko Otsuki

Keiko Mukaida

Kenshiro Kido

Ayako Sumii

Tsuyoshi Ikeda

Yuko Noda

Toshimichi Yasuda

Soshi Narasaki

Takahiro Kato

Satoshi Kamiya

Yousuke T Horikawa

Yasuo M Tsutsumi

Affiliations

Soon will be listed here.

Abstract

Remimazolam is a novel general anesthetic and its safety in patients with malignant hyperthermia (MH) is unknown. We used myotubes derived from the skeletal muscle of patients with MH to examine the response to ryanodine receptor 1 (RYR1) agonist and remimazolam in MH-susceptible patients. Patients underwent muscle biopsy for the Ca-induced Ca release (CICR) rate test, a diagnostic tool for MH in Japan. Ten patients had myotubes obtained from skeletal muscle cultures, and the genes associated with malignant hyperthermia in these patients were analyzed. The EC of caffeine, cresol, and remimazolam to induce intracellular calcium concentration change were compared between myotubes from CICR-negative genetic test patients and myotubes from other patients. Eight of the ten were CICR-positive, five of whom had RYR1 causative gene mutations or variants. Two patients had CICR-negative genetic tests, and as expected had the highest EC (the concentration of a drug that gives a half-maximal response) in response to caffeine, 4CmC and remimazolam. Three patients had a positive CICR but no known variants in RYR1 or CACNA1S (voltage-gated calcium channel subunit alpha1S). Myotubes in these patients had significantly lower EC50s for all agents than myotubes in CICR-negative patients. When myotubes from a patient who was CICR-negative and had no gene variant were used as a control, myotubes from CICR-positive patients were more hyper-responsive than controls to all stimulants used. The EC for remimazolam was lowest for myotubes from CICR-positive, RYR1-mutant patients, at 206 µM (corresponding to 123 µg/mL). The concentration was more than 80-times higher than the clinical concentration. gene variants in R4645Q and W5020G were shown to be causative gene mutations for MH. Intracellular calcium in myotubes from MH patients are elevated at high concentrations of remimazolam but not at clinically used concentrations of remimazolam. Remimazolam appears to be safe to use in patients with MH.

Citing Articles

Optimizing Pediatric Sedation: Evaluating Remimazolam and Dexmedetomidine for Safety and Efficacy in Clinical Practice.

Scheckenbach V, Fideler F Paediatr Drugs. 2024; 27(2):181-189.

PMID: 39485634 PMC: 11829837. DOI: 10.1007/s40272-024-00659-1.

Innovations in Phenotyping and Diagnostics Create Opportunities for Improved Treatment and Genetic Counseling for Rare Diseases.

Thompson M Genes (Basel). 2024; 15(6).

PMID: 38927651 PMC: 11203049. DOI: 10.3390/genes15060715.

References

Migita T, Mukaida K, Hamada H, Kobayashi M, Nishino I, Yuge O . Effects of propofol on calcium homeostasis in human skeletal muscle. Anaesth Intensive Care. 2009; 37(3):415-25. DOI: 10.1177/0310057X0903700313. View

Urabe T, Miyoshi H, Narasaki S, Yanase Y, Uchida K, Noguchi S . Characterization of intracellular calcium mobilization induced by remimazolam, a newly approved intravenous anesthetic. PLoS One. 2022; 17(2):e0263395. PMC: 8806057. DOI: 10.1371/journal.pone.0263395. View

Miyoshi H, Watanabe T, Kido K, Kamiya S, Otsuki S, Narasaki S . Remimazolam Requires Less Vasopressor Support during Induction and Maintenance of General Anesthesia in Patients with Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement: A Retrospective Analysis from a Single Center. Biomed Res Int. 2022; 2022:6386606. PMC: 9617702. DOI: 10.1155/2022/6386606. View

Hopkins P, Ruffert H, Snoeck M, Girard T, Glahn K, Ellis F . European Malignant Hyperthermia Group guidelines for investigation of malignant hyperthermia susceptibility. Br J Anaesth. 2015; 115(4):531-9. DOI: 10.1093/bja/aev225. View

Weigl L, Ludwig-Papst C, Kress H . 4-chloro-m-cresol cannot detect malignant hyperthermia equivocal cells in an alternative minimally invasive diagnostic test of malignant hyperthermia susceptibility. Anesth Analg. 2004; 99(1):103-107. DOI: 10.1213/01.ANE.0000118110.90277.D2. View

Wehner M, Rueffert H, Koenig F, Neuhaus J, Olthoff D . Increased sensitivity to 4-chloro-m-cresol and caffeine in primary myotubes from malignant hyperthermia susceptible individuals carrying the ryanodine receptor 1 Thr2206Met (C6617T) mutation. Clin Genet. 2002; 62(2):135-46. DOI: 10.1034/j.1399-0004.2002.620206.x. View

Gupta P, Bilmen J, Hopkins P . Anaesthetic management of a known or suspected malignant hyperthermia susceptible patient. BJA Educ. 2021; 21(6):218-224. PMC: 8134759. DOI: 10.1016/j.bjae.2021.01.003. View

Endo M . Calcium-induced calcium release in skeletal muscle. Physiol Rev. 2009; 89(4):1153-76. DOI: 10.1152/physrev.00040.2008. View

Janssens L, De Puydt J, Milazzo M, Symoens S, De Bleecker J, Herdewyn S . Risk of malignant hyperthermia in patients carrying a variant in the skeletal muscle ryanodine receptor 1 gene. Neuromuscul Disord. 2022; 32(11-12):864-869. DOI: 10.1016/j.nmd.2022.10.003. View

10.

Wehner M, Rueffert H, Koenig F, Meinecke C, Olthoff D . The Ile2453Thr mutation in the ryanodine receptor gene 1 is associated with facilitated calcium release from sarcoplasmic reticulum by 4-chloro-m-cresol in human myotubes. Cell Calcium. 2003; 34(2):163-8. DOI: 10.1016/s0143-4160(03)00072-1. View

11.

Johnston J, Dirksen R, Girard T, Hopkins P, Kraeva N, Ognoon M . Updated variant curation expert panel criteria and pathogenicity classifications for 251 variants for RYR1-related malignant hyperthermia susceptibility. Hum Mol Genet. 2022; 31(23):4087-4093. PMC: 9703808. DOI: 10.1093/hmg/ddac145. View

12.

Watanabe T, Miyoshi H, Noda Y, Narasaki S, Morio A, Toyota Y . Effects of Remimazolam and Propofol on Ca Regulation by Ryanodine Receptor 1 with Malignant Hyperthermia Mutation. Biomed Res Int. 2021; 2021:8845129. PMC: 7801102. DOI: 10.1155/2021/8845129. View

13.

Treves S, Anderson A, Ducreux S, Divet A, Bleunven C, Grasso C . Ryanodine receptor 1 mutations, dysregulation of calcium homeostasis and neuromuscular disorders. Neuromuscul Disord. 2005; 15(9-10):577-87. DOI: 10.1016/j.nmd.2005.06.008. View

14.

Kobayashi M, Mukaida K, Migita T, Hamada H, Kawamoto M, Yuge O . Analysis of human cultured myotubes responses mediated by ryanodine receptor 1. Anaesth Intensive Care. 2011; 39(2):252-61. DOI: 10.1177/0310057X1103900216. View

15.

White R, Schiemann A, Burling S, Bjorksten A, Bulger T, Gillies R . Functional analysis of RYR1 variants in patients with confirmed susceptibility to malignant hyperthermia. Br J Anaesth. 2022; 129(6):879-888. DOI: 10.1016/j.bja.2022.08.029. View

16.

Noda Y, Mukaida K, Miyoshi H, Nakamura R, Yasuda T, Saeki N . The effects of dantrolene in the presence or absence of ryanodine receptor type 1 variants in individuals predisposed to malignant hyperthermia. Anaesth Intensive Care. 2022; 50(4):312-319. DOI: 10.1177/0310057X211053644. View

17.

Ibarra M C, Wu S, Murayama K, Minami N, Ichihara Y, Kikuchi H . Malignant hyperthermia in Japan: mutation screening of the entire ryanodine receptor type 1 gene coding region by direct sequencing. Anesthesiology. 2006; 104(6):1146-54. DOI: 10.1097/00000542-200606000-00008. View

18.

Miyoshi H, Yasuda T, Otsuki S, Kondo T, Haraki T, Mukaida K . Several Ryanodine Receptor Type 1 Gene Mutations of p.Arg2508 Are Potential Sources of Malignant Hyperthermia. Anesth Analg. 2015; 121(4):994-1000. DOI: 10.1213/ANE.0000000000000886. View

19.

Ruffert H, Bastian B, Bendixen D, Girard T, Heiderich S, Hellblom A . Consensus guidelines on perioperative management of malignant hyperthermia suspected or susceptible patients from the European Malignant Hyperthermia Group. Br J Anaesth. 2020; 126(1):120-130. DOI: 10.1016/j.bja.2020.09.029. View

20.

Oku S, Mukaida K, Nosaka S, Sai Y, Maehara Y, Yuge O . Comparison of the in vitro caffeine-halothane contracture test with the Ca-induced Ca release rate test in patients suspected of having malignant hyperthermia susceptibility. J Anesth. 2003; 14(1):6-13. DOI: 10.1007/s005400050002. View